289 related articles for article (PubMed ID: 25389223)
1. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
[TBL] [Abstract][Full Text] [Related]
2. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani.
Kaur J; Sundar S; Singh N
J Antimicrob Chemother; 2010 Aug; 65(8):1742-8. PubMed ID: 20519355
[TBL] [Abstract][Full Text] [Related]
3. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
4. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
Bhaumik SK; Paul J; Naskar K; Karmakar S; De T
J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
Gopinath VS; Pinjari J; Dere RT; Verma A; Vishwakarma P; Shivahare R; Moger M; Kumar Goud PS; Ramanathan V; Bose P; Rao MV; Gupta S; Puri SK; Launay D; Martin D
Eur J Med Chem; 2013 Nov; 69():527-36. PubMed ID: 24095747
[TBL] [Abstract][Full Text] [Related]
7. In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis.
Mukkavilli R; Pinjari J; Patel B; Sengottuvelan S; Mondal S; Gadekar A; Verma M; Patel J; Pothuri L; Chandrashekar G; Koiram P; Harisudhan T; Moinuddin A; Launay D; Vachharajani N; Ramanathan V; Martin D
Eur J Pharm Sci; 2014 Dec; 65():147-55. PubMed ID: 25261338
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
[TBL] [Abstract][Full Text] [Related]
9. Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.
Thompson AM; O'Connor PD; Blaser A; Yardley V; Maes L; Gupta S; Launay D; Martin D; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
J Med Chem; 2016 Mar; 59(6):2530-50. PubMed ID: 26901446
[TBL] [Abstract][Full Text] [Related]
10. Novel arylimidamides for treatment of visceral leishmaniasis.
Wang MZ; Zhu X; Srivastava A; Liu Q; Sweat JM; Pandharkar T; Stephens CE; Riccio E; Parman T; Munde M; Mandal S; Madhubala R; Tidwell RR; Wilson WD; Boykin DW; Hall JE; Kyle DE; Werbovetz KA
Antimicrob Agents Chemother; 2010 Jun; 54(6):2507-16. PubMed ID: 20368397
[TBL] [Abstract][Full Text] [Related]
11. Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL).
Yang M; Arai C; Bakar Md A; Lu J; Ge JF; Pudhom K; Takasu K; Kasai K; Kaiser M; Brun R; Yardley V; Itoh I; Ihara M
J Med Chem; 2010 Jan; 53(1):368-73. PubMed ID: 19894726
[TBL] [Abstract][Full Text] [Related]
12. In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis.
Khanra S; Juin SK; Jawed JJ; Ghosh S; Dutta S; Nabi SA; Dash J; Dasgupta D; Majumdar S; Banerjee R
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008575. PubMed ID: 32866156
[TBL] [Abstract][Full Text] [Related]
13. Chromone linked nitrone derivative induces the expression of iNOS2 and Th1 cytokines but reduces the Th2 response in experimental visceral leishmaniasis.
Mallick S; Halder S; Dutta A; Dey S; Paul K; Maiti S; Bandyopadhyay C; Saha B; Pal C
Int Immunopharmacol; 2013 Apr; 15(4):772-9. PubMed ID: 23499679
[TBL] [Abstract][Full Text] [Related]
14. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response.
Melby PC; Chandrasekar B; Zhao W; Coe JE
J Immunol; 2001 Feb; 166(3):1912-20. PubMed ID: 11160239
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of artemisinin in experimental visceral leishmaniasis.
Sen R; Ganguly S; Saha P; Chatterjee M
Int J Antimicrob Agents; 2010 Jul; 36(1):43-9. PubMed ID: 20403680
[TBL] [Abstract][Full Text] [Related]
16. The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.
Patterson S; Wyllie S; Norval S; Stojanovski L; Simeons FR; Auer JL; Osuna-Cabello M; Read KD; Fairlamb AH
Elife; 2016 May; 5():. PubMed ID: 27215734
[TBL] [Abstract][Full Text] [Related]
17. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
Pinto EG; da Costa-Silva TA; Tempone AG
Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
[TBL] [Abstract][Full Text] [Related]
19. Aminothiazoles: Hit to lead development to identify antileishmanial agents.
Bhuniya D; Mukkavilli R; Shivahare R; Launay D; Dere RT; Deshpande A; Verma A; Vishwakarma P; Moger M; Pradhan A; Pati H; Gopinath VS; Gupta S; Puri SK; Martin D
Eur J Med Chem; 2015 Sep; 102():582-93. PubMed ID: 26318065
[TBL] [Abstract][Full Text] [Related]
20. Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis.
Van Bocxlaer K; Caridha D; Black C; Vesely B; Leed S; Sciotti RJ; Wijnant GJ; Yardley V; Braillard S; Mowbray CE; Ioset JR; Croft SL
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():129-138. PubMed ID: 30922847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
